

FOR IMMEDIATE RELEASE

IntegraGen Presents Data on microRNA Biomarker in Patients with Advanced Lung Cancer during 2015 European Lung Cancer Conference (ELCC)

miR-31-3p expression shown to be associated with overall survival and disease control rate in advanced lepidic adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors as first-line therapy

Geneva, Switzerland (April 16, 2015) - IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced that it [presented data](#) on the microRNA biomarker, miR-31-3p, during the 2015 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on a study of patients with advanced lung cancer, the data presented demonstrates that the expression of miR-31-3p is correlated with the histological type of the lung tumor, with a higher expression of the biomarker in mucinous type, and also identifies patients with a shorter progression-free survival. The results also indicate that miR-31-3p is associated with overall survival and disease control rate in a subgroup of patients with advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). The data presented was based on a post-hoc analysis of patients enrolled in two prospective, randomized controlled phase II trials of EGFR TKIs in patients with non-resectable pneumonic adenocarcinoma which were conducted by the **French Cooperative Thoracic Intergroup (IFCT)**.

“With the increasing use of EGFR TKIs in patients with lung cancer there is a need to identify molecular markers which can help guide clinicians to treat patients who are more likely to benefit from this class of drugs,” stated Professor Jacques Cadranel, a Member of the IFCT Scientific Council and coordinating investigator for both the IFCT-0401 and IFCT-0504 clinical trials from which samples for the study of miR-31-3p were obtained. “The results of our study provide initial evidence that patients with low expression levels of miR-31-3p may preferentially benefit from EGFR TKI therapy, especially patients with non-mucinous type adenocarcinoma of the lung.”

“These results demonstrate that there is a correlation between the expression of miR-31-3p in lung tumors and the effect of EGFR TKIs in patients with advanced NSCLC,” commented Francois Liebaert, M.D., IntegraGen’s Vice-President of R&D and Medical Affairs. “These findings parallel what we have previously reported from several large validation studies of the miR-31-3p biomarker in patients with metastatic colorectal cancer. Similar to our previous studies in colorectal cancer, miR-31-3p appears to be a biomarker which may aid clinicians in personalizing the care of lung cancer patients while also helping to avoid the use of ineffective drug therapies and their associated side effects and costs. Based on the results of this study, IntegraGen is exploring follow-up validation studies for the miR-31-3p biomarker in lung cancer patients.”

Lung cancer is the most common form of cancer worldwide with approximately 1.8 million cases diagnosed on an annual basis. Lung cancer is also the leading cause of cancer-related mortality being responsible for nearly one in five cancer-related deaths. The ELCC is an annual multidisciplinary meeting in the field of thoracic oncology, co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in partnership with other important societies representing thoracic oncology specialists including the European Society for Therapeutic Radiology and Oncology (ESTRO), the European Society of Thoracic Surgeons (ESTS), and the European Thoracic Oncology Platform (ETOP).

IntegraGen obtained the exclusive license for the worldwide rights for the miR-31-3p biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris, all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.

ABOUT THE IFCT

Created 16 years ago, the **French Cooperative Thoracic Intergroup** (IFCT) includes 470 physicians from various disciplines working in the field of lung cancer. The IFCT is an advocate of clinical studies and is supported by a national network of 250 centers (university hospitals, centers for the fight against cancer, general hospitals and private clinics). IFCT projects are coordinated by a Clinical Research Unit accredited by the National Cancer Institute (INCA) and the National League Against Cancer. Funded by various sources of public and industrial funds, the IFCT is strongly committed to conducting independent studies. The IFCT in figures: 600 investigators, 250 centers across France, nearly 9,000 patients included in 28 studies since 1999, and 11 current studies with active patient recruitment.

For more information on the IFCT visit www.ifct.fr

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of December 31, 2014, IntegraGen had 34 employees and generated revenue of €6 million during 2014. Based in the Evry Genopole, IntegraGen also has an office in the U.S. located in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel: +33 (0)1 60 91 09 00

NEWCAP.

Investor and Media Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tel: +33 (0)1 44 71 94 94